TherapeuticsMD, Inc. (NASDAQ:TXMD) – Analysts at Cantor Fitzgerald lifted their FY2017 earnings estimates for shares of TherapeuticsMD in a research report issued to clients and investors on Tuesday. Cantor Fitzgerald analyst W. Tanner now anticipates that the company will post earnings of ($0.35) per share for the year, up from their previous estimate of ($0.41). Cantor Fitzgerald has a “Buy” rating and a $33.00 price target on the stock. Cantor Fitzgerald also issued estimates for TherapeuticsMD’s FY2018 earnings at ($0.51) EPS.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The firm had revenue of $4.42 million for the quarter, compared to the consensus estimate of $5.36 million. During the same quarter last year, the business posted ($0.13) EPS. The company’s revenue for the quarter was down 19.7% on a year-over-year basis.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/18/fy2017-eps-estimates-for-therapeuticsmd-inc-raised-by-cantor-fitzgerald-txmd.html.

Several other brokerages have also recently weighed in on TXMD. BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 25th. Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a report on Friday, August 4th. Oppenheimer Holdings, Inc. set a $10.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a report on Thursday, August 17th. Jefferies Group LLC restated a “buy” rating and issued a $15.00 price objective on shares of TherapeuticsMD in a report on Friday, September 8th. Finally, Deutsche Bank AG set a $10.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $14.72.

Shares of TherapeuticsMD (NASDAQ:TXMD) opened at $5.85 on Friday. TherapeuticsMD has a 12 month low of $3.50 and a 12 month high of $8.30.

Hedge funds have recently modified their holdings of the business. Schwab Charles Investment Management Inc. lifted its position in TherapeuticsMD by 10.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock worth $3,659,000 after acquiring an additional 67,855 shares during the last quarter. Carl Domino Inc acquired a new stake in shares of TherapeuticsMD in the second quarter valued at approximately $235,000. Raymond James Financial Services Advisors Inc. raised its position in shares of TherapeuticsMD by 293.0% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 112,900 shares of the company’s stock valued at $595,000 after buying an additional 84,170 shares in the last quarter. Stifel Financial Corp raised its position in shares of TherapeuticsMD by 377.9% in the second quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock valued at $10,820,000 after buying an additional 1,622,668 shares in the last quarter. Finally, Bamco Inc. NY raised its position in shares of TherapeuticsMD by 126.8% in the second quarter. Bamco Inc. NY now owns 850,000 shares of the company’s stock valued at $4,479,000 after buying an additional 475,200 shares in the last quarter. Hedge funds and other institutional investors own 72.54% of the company’s stock.

In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of TherapeuticsMD stock in a transaction that occurred on Wednesday, August 30th. The stock was acquired at an average price of $5.99 per share, for a total transaction of $29,950.00. Following the completion of the acquisition, the director now owns 3,555 shares of the company’s stock, valued at approximately $21,294.45. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 23.92% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.